What is Spineology?
Spineology is a medical technology firm dedicated to transforming the field of spine surgery through the development of minimally invasive, high-performance solutions. The company is best known for its OptiMesh technology, which facilitates customizable lumbar fusion procedures, and its commitment to osseointegration. By focusing on patient-specific needs and surgical efficiency, Spineology provides surgeons with advanced tools designed to improve recovery times and clinical outcomes. The company operates at the intersection of engineering and clinical practice, addressing the critical demand for less invasive, more effective spinal interventions in an aging global population.
How much funding has Spineology raised?
Spineology has raised a total of $51.7M across 5 funding rounds:
Series B
$1.5M
Debt
$10.2M
Debt
$5M
Debt
$1M
Series A
$34M
Series B (2008): $1.5M with participation from Affinity Capital Management
Debt (2016): $10.2M, investors not publicly disclosed
Debt (2017): $5M supported by Hermed Capital co.,Ltd
Debt (2020): $1M featuring PPP
Series A (2024): $34M backed by 1315 Capital, RC Capital, and SV Health Investors
Key Investors in Spineology
1315 Capital
A healthcare-focused investment firm specializing in commercial-stage companies across pharma, medtech, and health services, providing operational expertise to drive growth.
RC Capital
A growth equity firm that targets high-potential healthcare companies, focusing on the synergy between medical devices, healthcare services, and digital health IT.
SV Health Investors
A specialist firm backing innovative life science and healthcare companies, offering active support and capital from early growth stages through to value creation.
What's next for Spineology?
With the recent influx of capital, Spineology is poised to enter a new phase of enterprise-level scaling. The strategic focus will likely shift toward expanding the commercial availability of its flagship OptiMesh and OptiLIF product lines, while simultaneously investing in research and development to maintain its competitive edge in osseointegration technology. By leveraging the expertise of its seasoned investor base, the company is expected to optimize its supply chain and broaden its market penetration among leading surgical centers. This phase of growth is critical for Spineology as it seeks to establish its minimally invasive platforms as the standard of care in lumbar fusion, ultimately driving long-term value for both clinical stakeholders and investors.
See full Spineology company page
